AKT1 and cancer: Inhibition of signaling pathways: mAbs can directly inhibit key signaling molecules within the cancer cell, such as protein kinase B (AKT) and extracellular signal-regulated kinase (ERK), thereby disrupting the proliferative and survival signals that are often dysregulated in cancer.